Kristen Hege, M.D., has served as a member of our Board of Directors since August 2016. Dr. Hege recently retired as Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb Company, or BMS, a global biopharmaceutical company, a position she held from November 2019, when BMS acquired Celgene Corporation, a pharmaceutical company, until March 2023. She joined Celgene Corporation in 2010 as Vice President, Translational Development. Dr. Hege has also held an active faculty position at the University of California, San Francisco Medical Center since 1996, most recently as Clinical Professor of Medicine, Hematology/Oncology, serving in that role as a volunteer since 2008. In February 2023, Dr. Hege was appointed to serve on the board of directors of Adaptimmune, effective as of November 1, 2023, and she has served on the board of directors of Graphite Bio, Inc., a biotechnology company, since April 2021. She also previously served as a director of Arcus Biosciences, Inc., a biopharmaceutical company, from October 2018 to November 2019. Dr. Hege received a B.A. in biochemistry summa cum laude from Dartmouth College and an M.D. from University of California, San Francisco.